Patent | Jotup

Vesselon Introduces the First On-site Co-formulation Platform that Dramatically Improves How Cells Receive and Act on Drugs

Retrieved on:

Monday, August 28, 2023

GREENWICH, Conn., Aug. 28, 2023 /PRNewswire/ -- Vesselon Inc. introduced the first on-site co-formulation platform that can enhance cellular uptake and response to therapy, without altering the active drug in any way. Compared to traditional administration methods, Vesselon drugs penetrate targeted cells more effectively and improve a drug's bioavailability by multiple fold.

Key Points:

Compared to traditional administration methods, Vesselon drugs penetrate targeted cells more effectively and improve a drug's bioavailability by multiple fold.
Without changing pharmaceutical manufacturing, CMC, or distribution practices, the platform can protect and differentiate an endless stream of blockbuster drugs.
"We encapsulate many different classes of drugs, from small molecules, monoclonal antibodies, nucleic acids to viruses," said Clay Larsen, CEO of Vesselon.
"I think the best way to think about our approach is that it changes the ability of tissues to receive and act on the drug.

HARMONY BIOSCIENCES REITERATES CONFIDENCE IN WAKIX® (PITOLISANT) PATENTS FOLLOWING FAVORABLE DECISION BY U.S. PATENT AND TRADEMARK OFFICE (USPTO) TO DENY PETITION FOR REEXAMINATION  

Retrieved on:

Monday, August 28, 2023

Harmony, Patent, Narcolepsy, Patient, Idiopathic hypersomnia, DSM-IV codes, Pharmaceutical industry

PLYMOUTH MEETING, Pa., Aug. 28, 2023 /PRNewswire/ -- Harmony Biosciences Holdings, Inc. ("Harmony" or the "Company") (Nasdaq: HRMY), a pharmaceutical company dedicated to developing and commercializing innovative therapies for patients with rare neurological diseases, today commented on the favorable decision by the U.S. Patent and Trademark Office (USPTO) to deny a Petition for Reexamination concerning a patent covering the active ingredient in WAKIX® (pitolisant).

Key Points:

PLYMOUTH MEETING, Pa., Aug. 28, 2023 /PRNewswire/ -- Harmony Biosciences Holdings, Inc. ("Harmony" or the "Company") (Nasdaq: HRMY), a pharmaceutical company dedicated to developing and commercializing innovative therapies for patients with rare neurological diseases, today commented on the favorable decision by the U.S. Patent and Trademark Office (USPTO) to deny a Petition for Reexamination concerning a patent covering the active ingredient in WAKIX® (pitolisant).
The Company issued the following statement:
We are pleased that the U.S. Patent and Trademark Office (USPTO) rejected a challenge to the validity of claims within the patent covering the active ingredient in WAKIX® (pitolisant), in line with our expectations.
This decision not only underscores our confidence in the strength of the WAKIX patent portfolio but also reinforces our belief in the potential of the WAKIX franchise.
We are proud of the work we do every day to address the unmet medical needs of patients living with rare neurological diseases.

Alnylam to Appeal Claim Construction Ruling on Two Patents Asserted Against Moderna

Retrieved on:

Friday, August 25, 2023

Professional Services, Patent Law, Health, Legal, COVID-19, Pharmaceutical, Biotechnology, Therapy, Delaware Court of Chancery, Delaware Court, Judgement, Medication, District court, Patent, Alnylam Pharmaceuticals, RNA interference, Pharmaceutical industry, Pfizer

To date, in two separate actions against Moderna, Alnylam has sought to recover reasonable compensation for Moderna’s infringement of five Alnylam patents that cover key lipid technology embedded in Moderna’s COVID-19 Vaccine, SPIKEVAX®.

Key Points:

To date, in two separate actions against Moderna, Alnylam has sought to recover reasonable compensation for Moderna’s infringement of five Alnylam patents that cover key lipid technology embedded in Moderna’s COVID-19 Vaccine, SPIKEVAX®.
On August 21, 2023, the Delaware Court issued an order construing certain claim terms in two of the asserted Alnylam patents.
In light of that order, Alnylam and Moderna have jointly agreed to final judgment of non-infringement of two of Alnylam’s patents.
The Delaware Court’s claim construction ruling did not impact Alnylam’s infringement contentions in its two separate suits against Pfizer.

United States Pharmaceutical Packaging & Labeling Market Insights Report 2023-2028 Featuring Key Vendors - Amcor, Aptar, Berry Global, Gerresheimer, & WestRock Pharmaceuticals - ResearchAndMarkets.com

Retrieved on:

Friday, August 25, 2023

Packaging, Pharmaceutical, Health, Manufacturing, Drug development, WestRock, Sale, Patent, Comprehension, OTC, Ageing, Rare, Autoimmunity, Pharmaceutical industry, Fine chemical

The "US Pharmaceutical Packaging & Labeling Market - Focused Insights 2023-2028" report has been added to ResearchAndMarkets.com's offering.

Key Points:

The "US Pharmaceutical Packaging & Labeling Market - Focused Insights 2023-2028" report has been added to ResearchAndMarkets.com's offering.
Pharmaceutical packaging plays a pivotal role in the pharmaceutical industry, encompassing the packaging process for pharmaceutical preparations.
Within this context, this report is a comprehensive exploration of the pharmaceutical packaging and labeling market in the US, offering invaluable insights into market size, forecasts, and trends.
It provides a thorough and up-to-date analysis of the US pharmaceutical packaging and labeling market, including its size, anticipated future trends, relevant market segments, and industry dynamics.

Analysis of the Global Automated Liquid Handling Systems Industry, 2023-2035: Rising Demand for Complex Biopharmaceuticals Spurs Laboratory Expansion Worldwide - ResearchAndMarkets.com

Retrieved on:

Friday, August 25, 2023

Biotechnology, Pharmaceutical, Health, Medical Supplies, Patent, System, University, Research, Thermo Fisher Scientific, USD, Acquisition, Investment, Agilent Technologies, Biophysical environment, Growth, Fine chemical, 3D printing, Tecan

Advanced technologies driving innovation in the life science sector are boosting demand for automated liquid handling systems, which can maximize assay throughput and accuracy.

Key Points:

Advanced technologies driving innovation in the life science sector are boosting demand for automated liquid handling systems, which can maximize assay throughput and accuracy.
These systems have gained significance due to the rising demand for complex biopharmaceuticals and the need for precise laboratory processes.
Automated liquid handling systems have emerged as a solution to these challenges, offering precise liquid transfer capabilities and maintaining sample integrity.
The automated liquid handling systems market features various stakeholders, including developers of automated pipetting systems and automated microplate washers.

Hesai Announces Initial Determination from ITC Administrative Law Judge Granting Hesai’s Motion to Terminate Patent Infringement Investigation Brought by Ouster

Retrieved on:

Friday, August 25, 2023

Heart, United States International Trade Commission, PALO, Vexatious litigation, Tariff Act, Complaint, District court, Patent, Tobacco Master Settlement Agreement, Administrative law, ITC, Velodyne, Safety, Lidar

On April 11, 2023, Ouster filed a complaint against Hesai and Hesai Technology Co., Ltd. in the United States District Court for the District of Delaware for alleged patent infringement (the “Delaware Action”).

Key Points:

On April 11, 2023, Ouster filed a complaint against Hesai and Hesai Technology Co., Ltd. in the United States District Court for the District of Delaware for alleged patent infringement (the “Delaware Action”).
On June 22, 2023, Hesai filed a motion to terminate the ITC Action.
In its motion, Hesai argued that Ouster’s infringement allegations are barred by a prior settlement and arbitration agreement between Hesai and Velodyne Lidar, Inc. (the “Settlement Agreement”).
On August 24, 2023, the presiding Administrative Law Judge (“ALJ”) issued an order granting Hesai’s motion to terminate the ITC Action.

Huawei and Ericsson Sign Long-Term Patent Cross-Licensing Agreement

Retrieved on:

Friday, August 25, 2023

ITU, IEEE, 3GPP, ICT, Wi-Fi, European Patent Office, IETF, SEP, Patent, Ericsson, European Patent Convention, Mobile phone, Huawei

"We are delighted to reach a long-term global cross-licensing agreement with Ericsson," said Alan Fan, Head of Huawei's Intellectual Property Department.

Key Points:

"We are delighted to reach a long-term global cross-licensing agreement with Ericsson," said Alan Fan, Head of Huawei's Intellectual Property Department.
"As major contributors of standard essential patents (SEPs) for mobile communication, the companies recognize the value of each other's intellectual property, and this agreement creates a stronger patent environment.
In 2022, Huawei topped the European Patent Office's applicant ranking for number of patent applications filed, with 4,505 applications.
Fan said, "This agreement is the result of intensive discussions that ensured the interests of both patent holders and implementers are served fairly."

Huawei and Ericsson Sign Long-Term Patent Cross-Licensing Agreement

Retrieved on:

Friday, August 25, 2023

ITU, IEEE, 3GPP, ICT, Wi-Fi, European Patent Office, IETF, SEP, Patent, Ericsson, European Patent Convention, Mobile phone, Huawei

"We are delighted to reach a long-term global cross-licensing agreement with Ericsson," said Alan Fan, Head of Huawei's Intellectual Property Department.

Key Points:

"We are delighted to reach a long-term global cross-licensing agreement with Ericsson," said Alan Fan, Head of Huawei's Intellectual Property Department.
"As major contributors of standard essential patents (SEPs) for mobile communication, the companies recognize the value of each other's intellectual property, and this agreement creates a stronger patent environment.
In 2022, Huawei topped the European Patent Office's applicant ranking for number of patent applications filed, with 4,505 applications.
Fan said, "This agreement is the result of intensive discussions that ensured the interests of both patent holders and implementers are served fairly."

BrainChip Continues to Expand IP Portfolio with Latest Australian Patent Issuance

Retrieved on:

Friday, August 25, 2023

Engineering, Semiconductor, Technology, Manufacturing, Software, Artificial Intelligence, Hardware, Spiking, IP Australia, ADR, ASX, Research, IP, Patent, BrainChip, OTCQX, Architecture, AI, Mobile phone

This technology is in the advanced stages of development for integration into the 2nd generation Akida IP, indicating its practical use in cutting-edge hardware.

Key Points:

This technology is in the advanced stages of development for integration into the 2nd generation Akida IP, indicating its practical use in cutting-edge hardware.
“Our growing IP portfolio is the result of more than 15 years of AI architecture research and development,” said Sean Hehir, CEO of BrainChip.
This patent from IP Australia further cements our leadership as the world’s first commercial producer of neuromorphic IP.”
BrainChip’s portfolio now comprises eighteen issued patents (12 US, 4 Australian, 1 European and 1 Chinese).
Around thirty patent applications remain pending in the US, Europe, Australia, Canada, Japan, Korea, India, Brazil, Russia, Mexico, and Israel.

Sparta Biomedical Celebrates Prestigious Recognition in MedTech and Significant Milestone

Retrieved on:

Thursday, August 24, 2023

Patent, Osteoarthritis, Weight-bearing, Elective surgery, United States Patent and Trademark Office, Von Ormy, Texas, Patient, Sport, Jogging, Medtech, Medical device

MORRISVILLE, N.C., Aug. 24, 2023 /PRNewswire/ -- Sparta Biomedical Inc, a pioneering medical technology company specializing in redefining osteoarthritis treatment, proudly reflects on a momentous period marked by significant recognition and notable achievements.

Key Points:

MORRISVILLE, N.C., Aug. 24, 2023 /PRNewswire/ -- Sparta Biomedical Inc, a pioneering medical technology company specializing in redefining osteoarthritis treatment, proudly reflects on a momentous period marked by significant recognition and notable achievements.
MedTech Innovator, a distinguished nonprofit accelerator and competition platform within the healthcare industry, identified Sparta Biomedical as an exceptional innovator in the realm of orthopedics.
Reflecting on this achievement, CEO Dushyanth Surakanti stated, "We were honored that Sparta was chosen for the 2023 MedTech Innovator cohort.
This recognition underscores our dedication to developing innovative solutions that empower patients to regain mobility and lead lives of fulfillment."